Global Fund issues TB reminder

19 September 2018

The status of tuberculosis (TB) as the world’s leading killer among infectious diseases has been underlined by the Global Fund amid a report’s claim of a funding gap of $3.5 billion in 2018 alone in the fight to end its deadly impact.

Released ahead of a United Nations meeting next week, the new World Health Organization (WHO) Global Tuberculosis Report 2018 also states that 36% of people with TB are missed – either undiagnosed, untreated or unreported. Approximately 10 million people fell ill with the disease in 2017, and 1.6 million of those died.

Set up to accelerate the end of AIDS, TB and malaria as epidemics, the Global Fund is a partnership between governments, civil society, the private sector and people affected by the diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK